Condition: Hypertensive Disorders of Pregnancy · Preeclampsia · Gestational Hypertension · Sponsor: Ohio State University
The objective is to conduct a double-blinded randomized controlled trial of atorvastatin vs. placebo among postpartum individuals with hypertensive disorders of pregnancy, to improve cardiovascular risk score postpartum. For this, 76 individuals with hypertensive disorders of pregnancy (HDP) will be randomized to atorvastatin 10mg or placebo, which will be started in the postpartum period after cessation of breast feeding and continued for 3 months.
This description comes directly from the study's public registry record.
Tracy C Bank, MD · 614-293-2222 · Tracy.Bank@osumc.edu
Maged Costantine, MD, MBA · 614-293-2222 · Maged.Costantine@osumc.edu
Always discuss trial participation with your own doctor first.
| The Ohio State University Wexner Medical Center OB/GYN Maternal and Fetal Medicine | Columbus, Ohio, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06632379